The Ultimate Exit Strategy

Dissatisfied with the returns of stocks in health care? Try death care! The announcement that Procept Inc. will merge with a company that sells funeral services on the Internet was another nail in the coffin for small-cap biotech stocks.

Dissatisfied with the returns of stocks in health care? Try death care! The announcement that Procept Inc.will merge with a company that sells funeral services on the Internet was another nail in the coffin for small-cap biotech stocks. Procept's new service business is not designed to synergize with its existing pharmaceutical development program; it is simply a good investment that can provide a decent return to existing shareholders, explains Procept CFO Michael Fitzgerald. The plan is for Procept to merge with funeral service amalgamator Heaven's Door Corp. Explains Fitzgerald, the funeral services industry is a $30 billion industry in the US, and it is ripe for consolidation. Comprised mainly of "mom and pop" shops, it has few big players. Fitzgerald predicts that it can benefit from economies of scale and computerization. Procept will not seek to be like Hillenbrand Industries Inc. which is fond of saying that it offers products "from the cradle to the grave" in operating separate health care and funeral services businesses under the same aegis.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Scrip

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By 

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.

Pfizer CEO Bourla ‘Cautiously Optimistic’ About Tariffs, Pricing Policies

 
• By 

Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By 

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.